Table 1 Basic features of the publications included in this meta-analysis (n = 20)
| Â | Â | Â | cancer type | No. of patients | BANCR expression | detection method | survival analysis | Â | HR statistics | hazard ratios (95% CI) | follow-up (month) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Study (Reference) | year | country | high | low | cut-off | |||||||||||||
| Â | Â | Â | total | LNM | HTS | DM | total | LNM | HTS | DM | Â | |||||||
Guo Q [34] | 2014 | China | CRC | 60 | 18 | 14 | 16 | – | 42 | 13 | 16 | – | qRT-PCR | OS | mean-value | NA | NA | NA |
He A [30] | 2016 | China | Bladder cancer | 54 | 19 | 1 | 9 | – | 35 | 3 | 30 | – | qRT-PCR | OS | NA | NA | NA | NA |
Liu T [27] | 2018 | China | PTC | 30 | 17 | 4 | – | – | 13 | 6 | – | – | qRT-PCR | OS | mean-value | directly | NA | 60 |
Li L [12] | 2015 | China | GC | 184 | 92 | 60 | 67 | 12 | 92 | 43 | 51 | 0 | qRT-PCR | OS | median | directly | 1.511(1.025–2.227) | 100 |
Liao T [24] | 2017 | China | PTC | 92 | 29 | 14 | 4 | – | 63 | 30 | 22 | – | qRT-PCR | – | NA | NA | NA | NA |
Liu Z [35] | 2016 | China | ESCC | 142 | 71 | 57 | 41 | 30 | 71 | 33 | 23 | 19 | qRT-PCR | OS | median | directly | 2.24(1.05–4.76) | 60 |
DFS | median | directly | 3.45(1.92–6.20) | |||||||||||||||
Lou K [33] | 2018 | China | BC | 65 | 34 | 24 | 18 | – | 31 | 13 | 6 | – | qRT-PCR | OS | NA | SC | 1.39(0.86–2.25) | 120 |
DFS | 1.48(0.83–2.64) | |||||||||||||||||
Shen X [29] | 2017 | China | CRC | 116 | 53 | 32 | – | – | 53 | 17 | – | – | qRT-PCR | OS | median | directly | 2.24(1.22–4.11) | 70 |
Sun M [19] | 2014 | China | NSCLC | 113 | 53 | 19 | 11 | – | 60 | 40 | 30 | – | qRT-PCR | OS | fold change | SC | 0.5(0.26–0.94) | 40 |
DFS | 0.34(0.18–0.64) | |||||||||||||||||
Wang D [36] | 2016 | China | EC | 30 | 15 | 6 | 7 | – | 15 | 1 | 1 | – | qRT-PCR | OS | median | NA | NA | NA |
Wang H [37] | 2016 | China | HCC | 108 | 43 | 29 | 35 | – | 65 | 23 | 20 | – | qRT-PCR | OS | mean-value | NA | NA | NA |
Jiang J [32] | 2018 | China | BC | 216 | 125 | 63 | 60 |  | 91 | 17 | 18 |  | qRT-PCR | OS | median | NA | 1.585(1.298–1.935) | 60 |
RFS | 1.532(1.272–1.844) | |||||||||||||||||
Zhang J [26] | 2018 | China | PTC | 60 | 17 | 6 | – | – | 43 | 30 | – | – | qRT-PCR | OS | NA | NA | NA | NA |
Sadeghpour [22] | 2018 | Iran | ESCC | 150 | 75 | – | 38 | 41 | 75 | – | 17 | 10 | qRT-PCR | OS | NA | NA | NA | NA |
Peng Z [23] | 2015 | China | Osteosarcoma | 84 | 42 | – | 30 | 20 | 42 | – | 16 | 14 | qRT-PCR | OS | median | directly | 2.934(1.12–7.67) | 60 |
Zhao N [16] | 2018 | China | HCC | 46 | 23 | – | 7 | – | 23 | – | 4 | – | qRT-PCR | OS | mean-value | NA | NA | NA |
Zhou T [17] | 2016 | China | HCC | 109 | 54 | – | 37 | – | 55 | – | 21 | – | qRT-PCR | OS | median | SC | 4.24(1.32–13.61) | 60 |
Su S [38] | 2015 | China | retinoblastoma | 60 | 30 | – | – | – | 30 | – | – | – | qRT-PCR | OS | median | directly | 2.9(1.05–8.03) | 60 |
Xue S [18] | 2018 | China | ccRCC | 62 | – | – | – | – | – | – | – | – | qRT-PCR | OS | NA | SC | 0.77(0.24–2.47) | 60 |
Chen Q [39] | 2018 | China | ESCC | 80 | 39 | 30 | – | – | 41 | 16 | – | – | qRT-PCR | NA | median | NA | – | NA |